Aldeyra Therapeutics Inc
aldeyra.comWhat Do They Do?
Develops experimental medicines for patients with immune-mediated diseases, including treatments for dry eye and allergic conjunctivitis and candidates for retinal and systemic conditions.
10-K for FY2025, filed Feb 27, 2026Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Feb 27, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$5.5MView ↗
- ▼ −44% (Loss)
- vs −$9.8M in Q2 FY2025
-
Jul 15, 2026
Company seeks FDA clarification and plans another meeting on reproxalap resubmission
It requested clarification of Type A meeting minutes and expects a Type D meeting by the end of the third quarter of 2026.
Sources
8-K, filed Jul 15, 2026
On July 14, 2026, Aldeyra Therapeutics, Inc. (Aldeyra) received minutes (the Minutes) from a Type A meeting, held on June 10, 2026 with the…View ↗
-
Mar 17, 2026
FDA declines reproxalap application for dry eye disease
The FDA did not raise safety or manufacturing concerns and did not recommend additional trials.
Sources
8-K, filed Mar 17, 2026
As reported under Item 7.01 of this Current Report on Form 8-K, on March 17, 2026, Aldeyra announced receipt of the 2026 Complete Response…View ↗
Reproxalap's target conditions
The older report describes reproxalap as a candidate for dry eye disease; the latest report also identifies allergic conjunctivitis as a potential use.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Feb 27, 2026We are a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. We are developing a…View ↗
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our…View ↗
Who Do They Compete With?
Competes with AbbVie, Johnson & Johnson, UCB, Amgen, Bristol-Myers Squibb, Eli Lilly and, Novartis, Regeneron Pharmaceuticals, Roche, Sanofi, Takeda, AstraZeneca, GlaxoSmithKline, Merck, and Pfizer
10-K for FY2025, filed Feb 27, 2026A myriad of new treatments have been or are being developed to treat inflammatory diseases, and have been used, or in theory could be used…View ↗
Loading...
